Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of Patients with Asthma

Next Previous
Trial Profile

A phase III trial of Patients with Asthma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rademikibart (Primary)
  • Indications Asthma
  • Focus Therapeutic Use

Most Recent Events

  • 31 Mar 2025 According to a Connect Biopharma media release, based on data from phase 2 trial the company received agreement from the U.S. Food and Drug Administration in an end-of-Phase 2 meeting with the Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation, to advance rademikibart into Phase 3 trials for the maintenance treatment of asthma.
  • 15 Dec 2023 New trial record
  • 12 Dec 2023 According to a Connect Biopharma media release, The Company plans to schedule an End of Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration to discuss rademikibart's Phase 3 regulatory path.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top